FDA approves Omontys for anemia in dialysis patientsOn March 29, the U.S. Food and Drug Administration (FDA) approved Omontys (peginesatide) to treat anemia in adult patients who had chronic kidney disease…
FDA approves Imbruvica to treat chronic lymphocytic leukemiaOn Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients who have…
Study: Radiation therapy skin reactions may be preventableSevere skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first day of…
A partnership to enhance outcomes through quality dashboards and actionLearn how a multidepartmental task force improved a hospital’s data display and action-planning tools
FDA approves marketing of postnatal test for developmental disabilitiesOn Jan. 17, the U.S. Food and Drug Administration (FDA) announce that it has authorized for marketing the Affymetrix CytoScan Dx Assay, which can…
The disappearing inpatientAs hospital admissions shrink, nursing jobs are shiftingto other areas, such as outpatient offices, clinics, postacute facilities, and home care.
FDA approves new stent for treatment of pseudocysts of the pancreasOn Dec. 18, the U.S. Food and Drug Administration (FDA) allowed marketing of the AXIOS Stent and Delivery System for treating pseudocysts that form…
FDA approves new treatment for genetic coagulation disorderOn Dec. 18, the U.S. Food and Drug Administration (FDA) approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for use in…
FDA approves first generic versions of CymbaltaOn Dec. 11, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Cymbalta (duloxetine delayed-release capsules). Read more.
FDA approves medical device for epilepsyThe U.S. Food and Drug Administration (FDA) has approved a device to help reduce the frequency of seizures in epilepsy patients who have not…
FDA issues safety communication for HeartStart AEDsOn Nov. 25, the U.S. Food and Drug Administration (FDA) issued a safety communication stating that certain HeartStart automated external defibrillator (AED) devices made…
Amazing apps: Space-age tools for cliniciansHealth apps hold the promise of greater access to medical services, better monitoring of chronic conditions, and improved patient outcomes.
FDA approves Omontys for anemia in dialysis patientsOn March 29, the U.S. Food and Drug Administration (FDA) approved Omontys (peginesatide) to treat anemia in adult patients who had chronic…
FDA approves Imbruvica to treat chronic lymphocytic leukemiaOn Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients…
Study: Radiation therapy skin reactions may be preventableSevere skin reactions during radiation therapy could be prevented by applying a thin transparent silicone dressing to the skin from the first…
A partnership to enhance outcomes through quality dashboards and actionLearn how a multidepartmental task force improved a hospital’s data display and action-planning tools
FDA approves marketing of postnatal test for developmental disabilitiesOn Jan. 17, the U.S. Food and Drug Administration (FDA) announce that it has authorized for marketing the Affymetrix CytoScan Dx Assay,…
The disappearing inpatientAs hospital admissions shrink, nursing jobs are shiftingto other areas, such as outpatient offices, clinics, postacute facilities, and home care.
FDA approves new stent for treatment of pseudocysts of the pancreasOn Dec. 18, the U.S. Food and Drug Administration (FDA) allowed marketing of the AXIOS Stent and Delivery System for treating pseudocysts…
FDA approves new treatment for genetic coagulation disorderOn Dec. 18, the U.S. Food and Drug Administration (FDA) approved Tretten, Coagulation Factor XIII A-Subunit (Recombinant), the first recombinant product for…
FDA approves first generic versions of CymbaltaOn Dec. 11, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Cymbalta (duloxetine delayed-release capsules). Read more.
FDA approves medical device for epilepsyThe U.S. Food and Drug Administration (FDA) has approved a device to help reduce the frequency of seizures in epilepsy patients who…
FDA issues safety communication for HeartStart AEDsOn Nov. 25, the U.S. Food and Drug Administration (FDA) issued a safety communication stating that certain HeartStart automated external defibrillator (AED)…
Amazing apps: Space-age tools for cliniciansHealth apps hold the promise of greater access to medical services, better monitoring of chronic conditions, and improved patient outcomes.
